Compare TTEK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | VRTX |
|---|---|---|
| Founded | 1966 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 96.6B |
| IPO Year | 1991 | 1991 |
| Metric | TTEK | VRTX |
|---|---|---|
| Price | $34.53 | $452.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 25 |
| Target Price | $43.25 | ★ $494.64 |
| AVG Volume (30 Days) | ★ 2.7M | 1.4M |
| Earning Date | 01-28-2026 | 11-03-2025 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.93 | ★ 14.22 |
| Revenue | $4,617,360,000.00 | ★ $11,723,300,000.00 |
| Revenue This Year | N/A | $11.01 |
| Revenue Next Year | $6.70 | $8.74 |
| P/E Ratio | $37.16 | ★ $31.78 |
| Revenue Growth | 6.84 | ★ 10.33 |
| 52 Week Low | $27.27 | $362.50 |
| 52 Week High | $42.98 | $519.68 |
| Indicator | TTEK | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 59.92 |
| Support Level | $33.27 | $433.81 |
| Resistance Level | $35.60 | $463.85 |
| Average True Range (ATR) | 0.88 | 10.71 |
| MACD | -0.04 | 0.51 |
| Stochastic Oscillator | 66.25 | 72.53 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.